ReviewSurgical oncology clinics of North America2019
Immunotherapy in Ovarian Cancer.
Review in Surgical oncology clinics of North America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Immune pathway through endometriosis to ovarian cancer.World journal of clinical oncology · 2024Review
- Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions.Life (Basel, Switzerland) · 2024Review
- Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- Deep learning-based segmentation of multisite disease in ovarian cancer.European radiology experimental · 2023Article
- The synergistic effect of EMT regulators and m6A modification on prognosis-related immunological signatures for ovarian cancer.Scientific reports · 2023Article
- Article
- Identification of fatty acid signature to predict prognosis and guide clinical therapy in patients with ovarian cancer.Frontiers in oncology · 2022Article
- Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.Cancer immunology, immunotherapy : CII · 2021Review
- Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.Cancer research · 2021Article
- MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer.Journal of ovarian research · 2021Article
- Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.Biomedicines · 2021Article
- Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer.Journal of cellular and molecular medicine · 2021Article
- Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype.iScience · 2021Article
- Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.Frontiers in genetics · 2021Article
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.PloS one · 2021Article
- Immunotherapy Advances for Epithelial Ovarian Cancer.Cancers · 2020Review
- Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.International journal of cancer · 2020Review
- Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The phenotype and functionalities of the major immune cell subsets including myeloid cells, macrophages, dendritic cells, and T cells are altered in the ovarian cancer microenvironment. Immunosuppressive networks including inhibitory B7 family members and regulatory T cell-associated adenosine pathway have been defined in human ovarian cancer. In this review, the authors integrate emerging information on immunosuppressive mechanisms and T cell phenotype and discuss strategies of immunotherapeutic and vaccine regimens. Finally, crucial points regarding design of immuno-oncology clinical trials are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.